Group 1 - The biopharma sector experienced a sluggish M&A activity in 2024, but the environment is expected to improve for deals in the remainder of 2025 [1] - The overall industry sentiment is shifting, indicating a potential increase in M&A transactions as market conditions become more favorable [1] - Factors contributing to the improved M&A landscape include evolving market dynamics and strategic interests among companies [1]

Group 1 - The session features Mohit Bansal, a Senior Equity Analyst at Wells Fargo, who specializes in biotech and pharma [1] - Greg Friberg, the EVP and Chief Research and Development Officer at BioMarin, is present for the discussion [1]